Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | MST1R | Q04912 | 1/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.50 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956179 | 0.86 | CA12 (0.48) | CLK4NTRK2DYRK1BTYRO3NTRK1 | |
| SCHEMBL20599741 | 0.86 | CA12 (0.48) | CLK4NTRK2DYRK1BTYRO3NTRK1 | |
| SCHEMBL13086372 | 0.83 | PARP10 (0.58) | PARP1PARP10F7F3GRM5 | |
| SCHEMBL15962134 | 0.77 | CLK4 (0.54) | CLK4NTRK2DYRK1BTYRO3NTRK1 | |
| SCHEMBL14847333 | 0.77 | GSK3B (0.58) | CLK4NTRK2DYRK1BTYRO3NTRK1 | |
| SCHEMBL29584703 | 0.76 | NTRK2 (0.56) | CLK4NTRK2DYRK1BTYRO3NTRK1 | |
| SCHEMBL4499446 | 0.76 | NTRK2 (0.56) | CLK4NTRK2DYRK1BTYRO3NTRK1 | |
| SCHEMBL27085978 | 0.75 | NTRK2 (0.51) | CLK4NTRK2DYRK1BTYRO3NTRK1 | |
| SCHEMBL14847331 | 0.74 | GSK3B (0.45) | CLK4NTRK1FLT3GSK3BBRAF | |
| SCHEMBL14847348 | 0.73 | CLK4 (0.51) | CLK4NTRK2DYRK1BTYRO3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4103559-B1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-115348961-B | Heterocyclic PAD4 inhibitors | 百时美施贵宝公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230079863-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-4103559-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115348961-A | Heterocyclic PAD4 inhibitors | 百时美施贵宝公司 | 2022-11-15 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2021163254-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | PADI6, PADI4, PADI1 | CLK4 3659/4885NTRK2 4122/4885DYRK1B 1254/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | CLK4 181/4885NTRK2 4025/4885DYRK1B 658/4885 |
| US-20230079863-A1 | KHK INHIBITORS | KHK, KHDRBS1, NADK | CLK4 2031/4885NTRK2 2940/4885DYRK1B 1821/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | CLK4 2031/4885NTRK2 2940/4885DYRK1B 1821/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | CLK4 3002/4885NTRK2 4343/4885DYRK1B 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.